Skip to main content
Article
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
Quantitative Health Sciences Publications and Presentations
  • David A. Amato, Dana-Farber Cancer Institute
  • Howard Bruckner, University of Rochester
  • DuPont Guerry, IV, Hospital of the University of Pennsylvania
  • Arlene S. Ash, University of Massachusetts Medical School
  • Geoffrey Falkson, University of Pretoria
  • Ernest C. Borden, University of Wisconsin
  • Richard H. Creech, Fox Chase Cancer Center
  • Edwin D. Savlov, University of Rochester
  • Thomas J. Cunningham, Albany Medical College
UMMS Affiliation
Department of Quantitative Health Sciences
Date
1-1-1987
Document Type
Article
Medical Subject Headings
Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; effects; Cyclophosphamide; Dactinomycin; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Mitolactol; Semustine
Abstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Rights and Permissions
Citation: Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's site
Related Resources
Link to Article in PubMed
Citation Information
David A. Amato, Howard Bruckner, DuPont Guerry, Arlene S. Ash, et al.. "Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma" Vol. 5 Iss. 3 (1987) ISSN: 0167-6997 (Linking)
Available at: http://works.bepress.com/arlene_ash/49/